|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||239.06 - 242.55|
|52-week range||129.21 - 275.87|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||36.44|
|Earnings date||26 Oct 2021|
|Forward dividend & yield||3.40 (1.42%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||N/A|
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from Eli Lilly and Company's (NYSE: LLY) SURPASS-4 clinical trial, which were published today in The Lancet. At 52 weeks, the highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7 kg (-25.8 lb., -13.0 percent) compared to re
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock.